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Objectives: The purpose of our study is to assess the frequency related to Diseases 
of the nervous system within out-patient care and determine the total health care 
expenses of them in Hungary in 2009. METHODS: CONCLUSIONS:  MethOds: Data 
were derived from the nationwidewide database of Hungarian National Health 
Insurance Fund Administration (NHIFA), based on official reports of outpatient care 
institutes. The 151 different types of treatment codes are listed in the chapter of 
the Guidelines of NHIFA for `Physiotherapists, massage-therapists, conductors and 
other physiotherapy practices`. The diseases of the nervous system are listed in 
the International Classification of Diseases (ICD) with code of G00-G99.  Results: 
Diseases of the nervous system account for 1.331.675 cases in the annual number 
of the physiotherapy-related activities (32318413 cases) showing an approximately 
4,12% prevalence. The following top-10 medical procedure were responsible for 48.48% 
(645562) of total activities: individual training (7.79 %), passive motion therapy on mul-
tiple limbs (6.24%),selective nerve stimulation therapy (5.89%), muscle strengthening 
exercise (5.82%), training for circulation improvement (4.6%), parts of the body per 
individual physiotherapy (4.19%), ergotherapy (3.78%), exercise to prevention of car-
diovascular complications (3.68%), Hand massage (3.53%), electrotherapy - facial nerve 
(2.96%). The total financial cost of all of the physiotherapeutic treatments provided in 
diseases of the nervous system was 388 million Hungarian Forint (1.25 million Euro) 
health insurance subsidy in 2009. cOnclusiOns: The 20 most frequent treatments 
accounts for 71.72 % (955073) of total services. The passive procedures are more com-
mon than the active in the 20 most commonly used activities list. Our results could 
be extremely useful for economic evaluation of the health care system and in the 
financial planning of the treatments of the studied diseases of the nervous system.
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iN mice: eviDeNce for iNvolvemeNt of oxiDAtive stress AND 
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Objectives: A wide body of literature suggest in vivo neuroprotective, antioxidant, 
anti-inflammatory and anti-ageing properties of Sesamol. This study was aimed 
to elucidate the protective effect of sesamol in experimental model of chronic 
fatigue syndrome (CFS). MethOds: Firstly, Sesamol was tested for its antidepres-
sant potential in mouse models using forced swim test (FST) and tail suspension 
test (TST). Later, Sesamol was examined in mouse model of chronic stress fatigue 
induced by chronic forced swimming for 15 days. Brain biochemical [superoxide 
dismutase (SOD), glutathione-S-transferase (GST), glutathione (GSH), lipid peroxi-
dation and nitrite levels) and plasma cytokines [tumour necrosis factor α (TNF-α ) 
and interleukin 6 (IL-6)] levels were assessed to correlate the possible mechanism 
of action associated with fatigue symptoms. Further, adrenal ascorbic acid meas-
urement was done to correlate corticosterone levels. Results: Mice administered 
with sesamol showed significant decrease in immobility time in acute FST and 
TST. Sesamol significantly attenuated progression of CFS in experimental model as 
compared to control. Sesamol also corrected the other cognitive deficits (locomo-
tor activity, motor activity, memory retention, hyperalgesia) associated with CFS. 
Furthermore, it rectified the diminished levels of antioxidant enzymes such as SOD, 
GST and GSH in brain and altered levels of proinflammatory cytokines (TNF-α and 
IL-6). cOnclusiOns: This finding suggests that anti-fatigue activity of sesamol 
against chronic induced fatigue in mice. The present outcome offers a therapeutic 
application of sesamol against CFS and also offers the scope for its development 
against neuropsychiatric disorders.
uriNAry/KiDNey DisorDers – clinical outcomes studies
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tADAlAfil iN beNigN ProstAtic hyPerPlAsiA: Protocol for the 
systemAtic review of ADverse eveNts
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Objectives: Benign prostatic hyperplasia (BPH) is an age related disorder, however 
its symptoms begin to appear in some men as early as age 40 years. As per estimates 
every second person has BPH by the age of 60 and 90% of individuals develop BPH 
by 85 years. Tadalafil is a selective PDE5 enzyme inhibitor approved to treat men 
with BPH. The aim is to systematically review the medical literature for randomized 
control trial and identify the adverse events (AE) associated with tadalafil use in 
BPH. MethOds: All published randomized controlled trials (RCTs) comparing tada-
lafil with a placebo or active interventions for the treatment of BPH with or without 
any co-morbidity (such as but not limited to erectile dysfunction) were sought from 
PubMed, EMBASE, Cochrane Library, and Google Scholar. Abstracts, titles and then 
the full-text manuscripts of all selected articles will be retrieved and assessed by 
two independent reviewers against the eligibility criteria. Disagreements over study 
inclusion will be resolved through discussion. A pre-designed data extraction form 
will be used by two reviewers for the extraction of AE and other study findings. 
Cochrane risk of bias assessment checklist will be used for the risk of bias assess-
ment. An Excel spreadsheet will be used to extract data from the selected articles. 
Descriptive and quantitative data synthesis will be done for AE reported in all the 
studies. Meta-analysis will be performed using RevMan (v5.0). Results: Though 
there are several studies assessing tadalafil use in erectile dysfunction, a system-
atic review/meta-analysis of the evidence reporting its AE profile when used for 
NeurologicAl DisorDers – health care use & Policy studies
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ProgrAmme iN JAPAN
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National Institute of Public Health, Saitama, Japan
Objectives: In Japan, the Specified Disease Treatment Research Programme pro-
vides copayment reduction or exemption for patients with 56 designated rare 
and intractable diseases/syndromes according to disease severity and patients’ 
income levels. The objective of this study is to examine the impact of the Specified 
Disease Treatment Research Programme on generic drug utilisation under the fee-
for-service payment system. MethOds: We extracted and analysed claims data 
with indication for Parkinson’s disease, which is subject to the Specified Disease 
Treatment Research Programme, from the Social Health Insurance claims data 
processed from February to April 2011. Extracted data were analysed in terms of 
patients’ age and income levels, types of public subsidy, prescribed places (clinic/
hospital or pharmacy) and pharmacologic classes. Results: During the three 
months, cumulative total number of 72,145 patients in Social Health Insurance 
programme were prescribed drugs for Parkinson’s disease, of which 10,013 were 
entitled to the Specified Disease Treatment Research Programme. Overall average 
generic utilisation rate is 15.46% on a volume basis. Average generic utilisation rate 
for those entitled to the Specified Disease Treatment Research Programme is 4.04%, 
whilst for patients eligible for medical assistance programme is 21.75%. Generic 
utilisation is fewer in the elderly than in the younger generation. cOnclusiOns: 
Our study finds low generic utilization rate for patients with Parkinson’s disease 
entitled to the Specified Disease Treatment Research Programme. This might be 
suggesting that without mandatory clinical guidelines nor guidance for generic 
substitution, the Specified Disease Treatment Research Programme has been pro-
moted branded prescribing under the fee-for-service system. Additional studies 
with other designated rare and intractable diseases/syndromes are expected to 
generalise the study result.
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Objectives: Acetyl-L-carnitine (ALC), as a constructive component in fatty acid 
metabolism, is considered a potential agent for peripheral neuropathic pain (PNP). 
We aimed to access the efficacy and safety of ALC for the treatment of patients 
with PNP. MethOds: We searched PubMed up to March 2014 for randomized 
controlled trials (RCTs) comparing ALC with placebo or other active medications 
in diabetic and non-diabetic PNP patients. Two reviewers independently screened 
for eligible studies, assessed risk of bias, and extracted data. Mean difference (MD) 
and 95% confidence interval (CI) were used for pooling continuous data. Results: 
Four RCTs compared ALC with placebo and reported in 3 articles (n = 523) were 
included. Compared with placebo, ALC significantly reduced Visual Analogue Scale 
(VAS) of PNP patients (MD, 1.28; 95%CI, 0.93-1.64, P < 0.00001). In the subgroup 
analysis, the efficacy of ALC on VAS was similar in different administration route 
(intramuscular-oral sequential subgroup: MD, 1.19; 95% CI, 0.34-2.04, P = 0.006; oral 
only subgroup: pooled MD, 1.15; 95% CI, 0.33-1.96, P = 0.006), and ALC appeared 
more effective in diabetic PNP patients than non-diabetic PNP patients (diabetic 
subgroup: MD, 1.47; 95% CI, 1.06-1.87, P < 0.00001; non-diabetic subgroup: MD, 0.71; 
95% CI, -0.01-1.43, P = 0.05). No severe adverse events related to ALC were reported. 
The common adverse events were pain, headache, paraesthesia, hyperesthesia, 
retching, biliary colic and gastrointestinal disorders. The rates of total adverse 
events were similar in ALC and control group. cOnclusiOns: ALC could reduce 
VAS in PNP patients with acceptable safety. However, further trials with larger 
population and longer follow-up are required to confirm these findings.
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Objectives: The aim of our study is to assess the utilization of out-patient care 
physiotherapy services related to cerebral palsy and other paralytic syndromes 
according to age and gender. MethOds: The data come from the financial data 
base of the National Health Insurance Fund Administration involving the year 
of 2009. The activity list was provided by the rulebook on the application of the 
activity code list in out-patient care. The Cerebral Palsy and other paralytic 
syndromes are listed in the International Classification of Diseases (ICD) with 
code of G80-G83. The number of cases in physiotherapy activities were deter-
mined per 10000 persons by age and gender in outpatient care, 2009. Results: 
Diseases of the nervous system account for 1331675 cases in the annual number 
of the physiotherapy-related activities (32318413 cases) showing an approxi-
mately 4.12% prevalence. The prevalence of the Cerebral Palsy and other para-
lytic syndromes were 31.56% in the group of of diseases of the nervous system. 
The average number of cases of physiotherapy activities per 10000 persons 
accounted for 433 cases in 2009. The average number of cases per 10000 persons 
for males and females were 508 cases for males and 364 cases for females. 
The high number of physiotherapy treatment is provided for both gender in 
the youngest age group and 60-74 age groups in male and 70-84 age groups 
in female. cOnclusiOns: The cerebral palsy and other paralytic syndromes 
at the diseases of the nervous system show high prevalence, indicating the 
importance of prevention.
